Cognito Therapeutics receives FDA breakthrough device designation for next-generation digital therapeutic in Alzheimer’s disease

Cognito Therapeutics

12 January 2021 - Breakthrough designation is based on positive outcomes from clinical studies, and will advance the industry’s first next-generation digital therapeutic to treat memory and cognition in Alzheimer’s disease.

Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today its lead product has received breakthrough device designation from the U.S. FDA for the treatment of cognitive and functional symptoms associated with Alzheimer’s disease. 

The product, a non-invasive neurostimulation device using gamma frequency technology, is the first in the Company’s pipeline of digital therapeutics for neurodegenerative diseases and other chronic indications.

Read Cognito Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder